Jump to content

LUNGevityHunter

Members
  • Posts

    27
  • Joined

  • Last visited

Profile Information

  • City
    Colleyville
  • US State (if applicable)
    TEXAS
  • Country
    United States
  • Gender
    Male
  • Status
    Not a patient

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

LUNGevityHunter's Achievements

  1. https://www.fda.gov/news-events/fda-voices/fda-seeks-patient-insight-call-applications-patient-engagement-collaborative Today, the FDA announced the call for applications for the next cohort of the Patient Engagement Collaborative (PEC). The PEC, established in 2018 in collaboration with the Clinical Trials Transformation InitiativeExternal Link Disclaimer (CTTI), is a group of patient organizations and individual representatives who discuss ways to enhance patient engagement. CTTI and the FDA collaborate to involve representatives with a variety of perspectives including patients, caregivers and representatives from diverse patient organizations. The PEC is run by the FDA’s Patient Affairs staff, which is dedicated to providing an inviting, welcoming and meaningful experience for patient communities to engage with the FDA. Representatives from the patient community who participate in the PEC include: Patients who have personal disease experience. Caregivers who have personal experience supporting someone with a health condition (e.g., a parent, child, partner, family member or friend). Representatives from patient groups who have direct or indirect disease experience. The PEC discusses topics such as: Creating new ways to collaborate with patient communities. Making patient engagement more systematic. Improving transparency through education and outreach. Enhancing communication between the FDA and patient communities.
  2. South Jersey hospital uses new robotic technology to detect lung cancer. Physicians will be able to sample small, previously unreachable, nodules https://www.njspotlight.com/video/south-jersey-hospital-uses-new-robotic-technology-to-detect-lung-cancer/
  3. COLUMBUS, Ohio – Ohio Gov. Mike DeWine today signed legislation that aims to raise awareness of the link between radon exposure and cancer risk by designating January as Radiation Awareness Month in Ohio. https://cancer.osu.edu/news/new-law-draws-awareness-to-link-between-radon-and-lung-cancer
  4. “LUNGevity Foundation Names NFN Scout, MA, PhD, as Community Champions Honoree. A well-regarded leader in health equity education, this month's honoree works to eliminate inequalities in cancer care within the LGBTQ community” https://www.prnewswire.com/news-releases/lungevity-foundation-names-nfn-scout-ma-phd-as-community-champions-honoree-301321400.html
  5. “The FDA has granted a breakthrough therapy designation from the FDA for patients with advanced non-small cell lung cancer with a KRASG12C mutation following prior systemic treatment.” https://www.targetedonc.com/view/fda-grants-breakthrough-therapy-designation-to-adagrasib-for-krasg12c-mutated-nsclc
  6. How the LUNGevity Foundation Is Empowering People with Late-Stage Lung Cancer: https://www.healthline.com/health/lung-cancer/hope-summit
  7. https://bluenotetherapeutics.com/post/cancer-distress-a-discussion-with-clinical-experts-from-mskcc/. A few weeks ago, a panel of patients and psycho-oncology experts from Memorial Sloan Kettering Cancer Center answered many questions regarding this topic. Questions like: What is the difference between cancer-related distress and normal, everyday stress? Does the treatment of cancer-related anxiety reduce a patient’s experience of physical pains that are associated with the disease? Has the stress level of cancer patients risen due to compromised immune systems and COVID? Is there such a thing as a stress roller-coaster that cancer patients experience? Is there a difference between fear of “progression of cancer” and “fear of recurrence”? How to ask for psycho-oncology help?
  8. TRIDENT-1 is enrolling participants in a Phase 2 multi-center study evaluating an investigational drug repotrectinib for the treatment of individuals with ROS1+ advanced non-small cell lung cancer (NSCLC) as well as individuals with NTRK+ advanced solid tumors. Patient Website link: http://trident1study.com Patient eBrochure link: https://online.flippingbook.com/view/462279568/
  9. FDA APPROVES LUMAKRASTM(SOTORASIB), THE FIRST AND ONLY TARGETED TREATMENT FOR PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER https://www.reuters.com/article/amgen-fda-lumakras-idUSL2N2ND2BA
  10. “Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive, resectable early-stage lung cancer, compared with best supportive careFirst and only cancer immunotherapy to show positive Phase III results in the adjuvant lung cancer setting. New adjuvant treatment options are urgently needed in early lung cancer to help the approximately 50% of people who currently experience recurrence following surgery”
  11. https://www.wtkr.com/news/new-national-campaign-aims-to-fight-against-lung-cancer
  12. https://www.targetedonc.com/view/capmatinib-addresses-subset-of-met-amplified-non-small-cell-lung-cancer
  13. https://www.medicalnewstoday.com/articles/how-it-works-immunotherapy-for-lung-cancer
  14. “No Small Challenge: Emerging Therapies in Small Cell Lung Cancer” https://www.curetoday.com/view/no-small-challenge-emerging-therapies-in-small-cell-lung-cancer
  15. Thank you, Tim. Congratulations on NED! You may have more options, if/when needed. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination. Our partners at EmergingMed offer a clinical trial navigation service- connect with them at 877-769-4834
×
×
  • Create New...